Evidence map›Paper›PMID 36624560›Full record

ArticleEuropean heart journal. Cardiovascular Imaging2023

Cardiac magnetic resonance in giant cell myocarditis: a matched comparison with cardiac sarcoidosis.

Pauli Pöyhönen, Hanna-Kaisa Nordenswan, Jukka Lehtonen, Suvi Syväranta, Chetan Shenoy, Markku Kupari

Open access · hybridAbstract read
In one paragraph

Article in European heart journal. Cardiovascular Imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Cardiac magnetic resonance in histologically proven eosinophilic myocarditis.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2023
    Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Pauli PöyhönenHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029 Helsinki, Finland.ORCID 0000-0002-3031-5391
Hanna-Kaisa NordenswanHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029 Helsinki, Finland.ORCID 0000-0003-0114-114X
Jukka LehtonenHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029 Helsinki, Finland.
Suvi SyvärantaRadiology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029 Helsinki, Finland.ORCID 0000-0003-1889-3858
Chetan ShenoyUniversity of Minnesota Medical School, Cardiovascular Division, Department of Medicine, 420 Delaware St SE, MMC 508, Minneapolis, Minnesota 55455, USA.ORCID 0000-0001-8877-4999
Markku KupariHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00029 Helsinki, Finland.ORCID 0000-0002-5813-3477
University of Helsinki · FIUniversity of Minnesota Medical Center · US

Funding

Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac SarcoidosisR03HL157011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2021 to 2022
$155k
6 · The paper itself

Abstract

aimsGiant cell myocarditis (GCM) is an inflammatory cardiomyopathy akin to cardiac sarcoidosis (CS). We decided to study the findings of GCM on cardiac magnetic resonance (CMR) imaging and to compare GCM with CS. METHODS AND

resultsCMR studies of 18 GCM patients were analyzed and compared with 18 CS controls matched for age, sex, left ventricular (LV) ejection fraction and presenting cardiac manifestations. The analysts were blinded to clinical data. On admission, the duration of symptoms (median) was 0.2 months in GCM vs. 2.4 months in CS (P = 0.002), cardiac troponin T was elevated (>50 ng/L) in 16/17 patients with GCM and in 2/16 with CS (P < 0.001), their respective median plasma B-type natriuretic propeptides measuring 4488 ng/L and 1223 ng/L (P = 0.011). On CMR imaging, LV diastolic volume was smaller in GCM (177 ± 32 mL vs. 211 ± 58 mL, P = 0.014) without other volumetric or wall thickness measurements differing between the groups. Every GCM patient had multifocal late gadolinium enhancement (LGE) in a distribution indistinguishable from CS both longitudinally, circumferentially, and radially across the LV segments. LGE mass averaged 17.4 ± 6.3% of LV mass in GCM vs 25.0 ± 13.4% in CS (P = 0.037). Involvement of insertion points extending across the septum into the right ventricular wall, the "hook sign" of CS, was present in 53% of GCM and 50% of CS.

conclusionIn GCM, CMR findings are qualitatively indistinguishable from CS despite myocardial inflammation being clinically more acute and injurious. When matched for LV dysfunction and presenting features, LV size and LGE mass are smaller in GCM.

Indexed as

CardiomyopathiesMyocarditisSarcoidosisContrast MediaGadoliniumGiant CellsHumansMagnetic Resonance Imaging, CineMagnetic Resonance SpectroscopyPredictive Value of TestsContrast MediaGadoliniumcardiac magnetic resonancecardiac sarcoidosisgiant cell myocarditis

Identifiers

PMID36624560
PMCPMC10029848
OpenAlexW4313892725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.